Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.58
-0.09 (-1.59%)
Jul 22, 2026, 10:57 AM EDT - Market open
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.78 billion as of July 22, 2026. Its market cap has increased by 169.74% in one year.
Market Cap
1.78B
Enterprise Value
1.59B
1-Year Change
169.74%
Ranking
Category
Stock Price
$5.58
ChartMarket Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.78B, an increase of 158.51%. That is a compound annual growth rate of 17.70%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 22, 2026 | 1.78B | 18.47% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Tyra Biosciences | 1.85B |
| Nanobiotix | 1.81B |
| Precigen | 1.81B |
| Maravai LifeSciences Holdings | 1.80B |
| Bicara Therapeutics | 1.78B |
| Palvella Therapeutics | 1.78B |
| Sarepta Therapeutics | 1.78B |
| AbCellera Biologics | 1.77B |